Todd Louis Rosenblat MD
Hematologic Oncology
Assistant Professor of Medicine at Columbia University Medical Center, Div. of Hematology/Oncology New York-Presbyterian Hospital/Columbia University Medical Center
622 W 168th StNew York, NY 10032
Overview of Dr. Rosenblat
Dr. Todd Rosenblat is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 14 years. Dr. Rosenblat accepts several types of health insurance, listed below. He is one of 79 doctors at New York-Presbyterian Hospital and one of 24 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. He has more than 20 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2003 - 2006
Stony Brook University Health Sciences Center School of MedicineClass of 2003
Certifications & Licensure
NY State Medical License 2004 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts TouchWorks EHR, Allscripts, 2016-2017
Clinical Trials
- Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Start of enrollment: 2010 Jun 01
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Publications & Presentations
PubMed
- First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level.Naveen Pemmaraju, Marco Herling, Kendra L Sweet, Anthony S Stein, Sumithira Vasu
Haematologica. 2026-01-15 - Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.Marina Konopleva, Naveen Pemmaraju, Kendra L Sweet, Anthony S Stein, David A Rizzieri
Cancer. 2026-01-01 - Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial.Naveen Pemmaraju, Marina Konopleva, Kendra L Sweet, Anthony S Stein, David A Rizzieri
Leukemia & Lymphoma. 2025-07-01
Abstracts/Posters
- Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution ExperienceTodd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Todd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...Todd L. Rosenblat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPOMultiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
